Eli Lilly And Co (NYSE:LLY) has officially become the giant quietly moving the strings behind a large slice of the pharma ETF universe. With blockbuster revenue growth, repeated earnings beats and a pipeline that refuses to slow down, Lilly isn’t just lifting its own stock – it’s powering a growing cluster of healthcare ETFs that now allocate double-digit weight to the drugmaker.
Today, roughly 15 ETFs give Lilly a double-digit footprint – making the company one of the most influential single-stock drivers of healthcare fund performance. And with pharma stocks delivering strong third-quarter scorecards of the year, Lilly’s outsized role is becoming impossible to ignore.
